Trimethoprim

The dosage of Trimethoprim is determined by the severity of the infection and the patient's renal function. For the treatment of acute, uncomplicated urinary tract infections, the standard adult dosage is:

• Standard Dose: 100 mg every 12 hours (twice daily) or 200 mg once daily.
• Duration: Typically prescribed for 10 days, although some clinicians may utilize shorter 3-day courses for specific uncomplicated cases in women, as supported by some clinical trials.
• Prophylaxis (Off-label): For the prevention of recurrent UTIs, a lower dose of 100 mg once daily, usually at bedtime, may be prescribed for several months.

Trimethoprim is used in pediatric patients primarily for the treatment of UTIs and occasionally for otitis media (middle ear infection).

• Children (age 2 months and older): The usual dosage is 4 mg/kg to 6 mg/kg per day, divided into two equal doses every 12 hours.
• Maximum Dose: The total daily dose should not exceed the adult maximum of 200 mg per day.
• Infants (under 2 months): Safety and efficacy have not been established for infants under 2 months of age, and use is generally avoided due to the risk of interfering with folate metabolism during critical growth phases.

Renal Impairment

Since Trimethoprim is primarily cleared by the kidneys, dosage adjustments are mandatory for patients with decreased renal function to prevent drug accumulation and toxicity.

• Creatinine Clearance (CrCl) 15-30 mL/min: The dose should be reduced by 50% (e.g., 50 mg twice daily instead of 100 mg).
• CrCl < 15 mL/min: Use of Trimethoprim is generally not recommended in patients with severe renal failure unless dialysis is available and levels can be monitored.

Hepatic Impairment

While the liver plays a minor role in Trimethoprim metabolism, caution should be exercised in patients with severe hepatic dysfunction. No specific dosage adjustment formulas exist, but clinical monitoring for adverse effects is advised.

Elderly Patients

Geriatric patients often have age-related declines in renal function. Dosing should be initiated at the lower end of the range, and kidney function (serum creatinine) should be assessed before and during treatment. The risk of hyperkalemia (high potassium) is significantly higher in this population.

To ensure the best results and minimize side effects, follow these administration guidelines:

• Consistency: Take the medication at the same time(s) each day to maintain a steady level of the drug in your bloodstream.
• Hydration: Drink plenty of water (at least 8 ounces) with each dose and throughout the day. This helps the kidneys process the medication and flush the urinary tract.
• Food: Trimethoprim may be taken with or without food. If the medication causes stomach upset, taking it with a meal or a snack may help.
• Complete the Course: It is vital to finish the entire prescription even if symptoms improve after a few days. Stopping early can allow the remaining bacteria to multiply and develop resistance to the antibiotic.
• Storage: Store tablets at room temperature (20°C to 25°C or 68°F to 77°F) in a dry place away from direct sunlight.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of side effects.

Acute overdose of Trimethoprim can lead to serious complications. Symptoms may include severe nausea, vomiting, dizziness, headache, mental depression, and confusion. Chronic overdosage (taking too much over a long period) can result in bone marrow depression, manifested as thrombocytopenia (low platelets) or leukopenia (low white blood cells).

• Emergency Action: If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Gastric lavage or induction of emesis (vomiting) may be required if the ingestion was recent.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as this can lead to treatment failure or antibiotic resistance.

Trimethoprim is generally well-tolerated, but some patients may experience mild to moderate side effects. The most frequently reported adverse reactions include:

• Dermatologic Reactions: Pruritus (itching) and maculopapular rash (flat, red areas covered with small bumps) are the most common. These usually appear 7 to 14 days after starting therapy and are often mild.
• Gastrointestinal Upset: Nausea, vomiting, and epigastric distress (stomach ache) may occur. These are typically transient and can be mitigated by taking the drug with food.
• Taste Alterations: Some patients report an abnormal or bitter taste in the mouth (dysgeusia).

• Glossitis: Inflammation of the tongue, which may appear red, swollen, or smooth.
• Stomatitis: Inflammation of the mucous membranes in the mouth, sometimes leading to small sores.
• Headache and Dizziness: Mild neurological symptoms that usually resolve without discontinuing the medication.
• Photosensitivity: An increased sensitivity of the skin to sunlight, which can lead to easier sunburn.

• Aseptic Meningitis: A rare but serious reaction characterized by fever, headache, stiff neck, and confusion. This is a non-infectious inflammation of the brain lining.
• Cholestatic Jaundice: A condition where bile flow from the liver is blocked, leading to yellowing of the skin and eyes.
• Hematologic Abnormalities: These include megaloblastic anemia (large, dysfunctional red blood cells), neutropenia (low white blood cells), and thrombocytopenia (low platelets). These are more common in patients with pre-existing folate deficiency.

While rare, certain side effects require urgent medical intervention.

> Warning: Stop taking Trimethoprim and call your doctor immediately if you experience any of these:

• Severe Allergic Reactions (Anaphylaxis): Symptoms include hives, difficulty breathing, swelling of the face, lips, tongue, or throat, and a rapid heartbeat.
• Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN): These are life-threatening skin reactions. Watch for flu-like symptoms followed by a painful red or purplish rash that spreads and causes blistering and peeling.
• Hyperkalemia (High Potassium): Trimethoprim can act like a potassium-sparing diuretic. Symptoms include muscle weakness, irregular heartbeat (arrhythmia), and tingling sensations. This is especially dangerous for patients with kidney disease or those taking heart medications.
• Clostridioides difficile-Associated Diarrhea (CDAD): Like most antibiotics, Trimethoprim can disrupt the gut microbiome. Seek help for severe, watery, or bloody diarrhea, even if it occurs weeks after stopping the drug.
• Blood Dyscrasias: Signs include unusual bruising, bleeding (nosebleeds, bleeding gums), extreme fatigue, or frequent infections (fever, sore throat).

Prolonged use of Trimethoprim (for prophylaxis) can lead to certain chronic issues:

• Folate Depletion: Because Trimethoprim interferes with folate metabolism, long-term use can lead to a deficiency. Healthcare providers may recommend folic acid or folinic acid supplements to counteract this.
• Renal Function Changes: Long-term use requires periodic monitoring of serum creatinine, as the drug can interfere with the tubular secretion of creatinine, potentially masking true kidney function or causing a mild, reversible rise in creatinine levels.
• Antibiotic Resistance: Extended use increases the risk that bacteria in the body will become resistant to Trimethoprim, making future infections harder to treat.

Currently, there are no FDA black box warnings specifically for Trimethoprim monotherapy. However, it is important to note that the combination product (Trimethoprim/Sulfamethoxazole) carries significant warnings regarding severe skin reactions and blood disorders, which patients should be aware of if they are switched between these medications.

Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment remains safe and effective.

Trimethoprim is a targeted antibiotic that requires careful clinical oversight. It is not effective against viral infections like the common cold or flu. Using antibiotics when they are not needed increases the risk of developing drug-resistant infections later. Patients should be screened for a history of folate deficiency and renal impairment before starting therapy.

No FDA black box warnings for Trimethoprim monotherapy. (Note: This differs from the combination product Trimethoprim-Sulfamethoxazole).

• Hematologic Toxicity: Trimethoprim may interfere with human folate metabolism, particularly during prolonged high-dose therapy. This can lead to bone marrow suppression. Patients with pre-existing folate deficiency (e.g., the elderly, chronic alcoholics, or those with malabsorption syndromes) are at higher risk for developing anemia, leukopenia, and thrombocytopenia.
• Hyperkalemia Risk: Trimethoprim has been shown to inhibit the renal excretion of potassium, similar to the action of the diuretic amiloride. This can lead to dangerously high levels of potassium in the blood (hyperkalemia). The risk is highest in patients with underlying renal dysfunction, those of advanced age, and those taking other medications that increase potassium (such as ACE inhibitors or ARBs).
• Severe Skin Reactions: Although rare with monotherapy, life-threatening dermatological conditions like Stevens-Johnson Syndrome (SJS) have been reported. Any new rash should be reported to a physician immediately.
• Pseudomembranous Colitis: Treatment with Trimethoprim alters the normal flora of the colon and may permit overgrowth of Clostridioides difficile. This can range in severity from mild diarrhea to fatal colitis.

If you are taking Trimethoprim for an extended period (more than two weeks) or have underlying health conditions, your healthcare provider may require the following tests:

• Complete Blood Count (CBC): To monitor for signs of bone marrow suppression (white cells, red cells, and platelets).
• Renal Function Tests: Serum creatinine and BUN (Blood Urea Nitrogen) levels to ensure the kidneys are clearing the drug effectively.
• Serum Potassium: Particularly in the elderly or those with heart/kidney conditions, to monitor for hyperkalemia.
• Liver Function Tests: To check for rare instances of drug-induced hepatitis or cholestasis.

Trimethoprim generally does not interfere with the ability to drive or operate heavy machinery. However, some patients may experience dizziness or headache as a side effect. If you feel dizzy or less alert than usual, avoid these activities until you know how the medication affects you.

There is no direct contraindication between Trimethoprim and alcohol. However, alcohol can dehydrate the body and weaken the immune system, which may slow the recovery from a urinary tract infection. Additionally, chronic alcohol use increases the risk of folate deficiency, which can exacerbate the hematologic side effects of Trimethoprim.

Unlike some medications for chronic conditions, Trimethoprim does not typically require a tapering schedule. However, it is critical not to stop the medication early just because symptoms disappear. Discontinuing the drug before the bacteria are fully eradicated can lead to a relapse of the infection and the development of antibiotic resistance.

> Important: Discuss all your medical conditions, especially kidney disease, liver disease, and any history of anemia, with your healthcare provider before starting Trimethoprim.

• Dofetilide: Trimethoprim can increase the plasma concentrations of dofetilide (an anti-arrhythmic) by inhibiting its renal clearance. This significantly increases the risk of QT prolongation and life-threatening ventricular arrhythmias (Torsades de Pointes). This combination should be avoided.

• ACE Inhibitors and ARBs (e.g., Lisinopril, Losartan): Both Trimethoprim and these blood pressure medications can increase serum potassium levels. Concurrent use significantly increases the risk of severe hyperkalemia, particularly in elderly patients or those with renal impairment. Close monitoring of potassium levels is required.
• Methotrexate: Trimethoprim can increase the toxicity of methotrexate by displacing it from protein binding sites and competing for renal tubular secretion. Furthermore, both drugs are folate antagonists, which can lead to severe bone marrow suppression.
• Warfarin: Trimethoprim may enhance the anticoagulant effect of warfarin, increasing the risk of bleeding. The mechanism is thought to involve the displacement of warfarin from albumin and the inhibition of its metabolism. INR levels should be monitored closely if these drugs are used together.
• Phenytoin: Trimethoprim can inhibit the metabolism of phenytoin (an anti-seizure medication), leading to toxic levels of phenytoin in the blood. Signs of toxicity include ataxia (loss of coordination), nystagmus (involuntary eye movement), and mental confusion.

• Digoxin: Trimethoprim may increase digoxin levels by decreasing its renal tubular secretion. This is more common in elderly patients and can lead to digoxin toxicity (nausea, visual halos, arrhythmias).
• Repaglinide and Pioglitazone: Trimethoprim is an inhibitor of the CYP2C8 enzyme, which metabolizes these diabetes medications. This can lead to increased levels of the drugs and a higher risk of hypoglycemia (low blood sugar).
• Spironolactone: Like Trimethoprim, spironolactone is a potassium-sparing agent. Using them together requires extreme caution and frequent potassium checks.

• Potassium-Rich Foods: While generally healthy, an excessive intake of high-potassium foods (like bananas, spinach, and salt substitutes) while on Trimethoprim may contribute to the risk of hyperkalemia in susceptible individuals.
• Folic Acid: While folic acid supplements may be needed for those with deficiency, high doses of folic acid might theoretically reduce the effectiveness of Trimethoprim, although this is rarely clinically significant for treating UTIs.

• St. John’s Wort: May potentially induce the metabolism of Trimethoprim, though the clinical significance is low.
• Potassium Supplements: These should be avoided unless specifically directed by a doctor, due to the hyperkalemia risk.

• Serum Creatinine: Trimethoprim can interfere with the Jaffe alkaline picrate reaction, leading to a false elevation of serum creatinine by about 10%. It also inhibits the tubular secretion of creatinine. This does not represent a true decrease in glomerular filtration rate (GFR) but can complicate the interpretation of kidney function tests.
• Methotrexate Assays: Trimethoprim can interfere with competitive binding protein techniques used to measure methotrexate levels.

> Important: Tell your doctor about ALL medications, vitamins, supplements, and herbal products you are taking. A comprehensive review is necessary to prevent dangerous interactions.

Trimethoprim must NEVER be used in the following circumstances:

• Hypersensitivity: Patients with a known allergy or hypersensitivity to Trimethoprim or any component of the formulation. An allergic reaction may manifest as severe rash, swelling, or anaphylaxis.
• Megaloblastic Anemia due to Folate Deficiency: Because Trimethoprim is a dihydrofolate reductase inhibitor, it can worsen anemia caused by a lack of folate. Using it in these patients can lead to a dangerous drop in blood cell counts.
• Severe Renal Impairment (CrCl < 15 mL/min): When the kidneys cannot effectively clear the drug, the risk of systemic toxicity becomes unacceptably high.
• Infants under 2 months: The risk of interfering with folate metabolism and the potential for kernicterus (brain damage from high bilirubin) makes it contraindicated in newborns.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Pre-existing Bone Marrow Suppression: Patients with low white blood cell counts or low platelets should be monitored extremely closely, as Trimethoprim can further suppress the bone marrow.
• Mild to Moderate Renal Impairment: Requires significant dose adjustments and frequent monitoring of blood chemistry.
• Hepatic Disease: Since some metabolism occurs in the liver, patients with cirrhosis or hepatitis require cautious use.
• Elderly Patients: Due to the high risk of hyperkalemia and undiagnosed renal decline, Trimethoprim is used with caution in the geriatric population.

While Trimethoprim is not a sulfonamide, it is often used with them. Patients who have had severe reactions to the combination product (Bactrim/Septra) must be evaluated to determine if the reaction was to the Trimethoprim component or the Sulfamethoxazole component. If the previous reaction was Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis, Trimethoprim should be avoided unless the cause is definitively known.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies or blood disorders, before prescribing Trimethoprim.

Trimethoprim is classified as FDA Pregnancy Category C. It crosses the placenta and, due to its mechanism as a folate antagonist, there is a theoretical risk of causing birth defects, particularly neural tube defects (like spina bifida), if used during the first trimester.

• First Trimester: Use should be avoided unless the potential benefit outweighs the risk to the fetus. Folic acid supplementation is usually recommended if use is necessary.
• Later Trimesters: While less risky than the first trimester, it should still be used only when essential. Some studies suggest a risk of cardiovascular malformations or oral clefts with early exposure.
• Fertility: There is no definitive evidence that short-term use of Trimethoprim affects human fertility.

Trimethoprim is excreted in human breast milk. While the amount an infant receives is generally low, the drug can interfere with the infant's folate metabolism.

• Risk-Benefit: The American Academy of Pediatrics considers Trimethoprim to be usually compatible with breastfeeding, but caution is advised.
• Monitoring: The nursing infant should be monitored for signs of jaundice, rash, or diarrhea. Use should be avoided if the infant is premature or has hyperbilirubinemia.

Trimethoprim is approved for use in children 2 months of age and older for the treatment of urinary tract infections. It is not approved for use in infants younger than 2 months due to the risk of interfering with folate-dependent growth processes. In older children, dosing is weight-based, and the liquid solution is preferred for accuracy. Long-term use in children requires monitoring of blood counts.

Elderly patients are at a significantly higher risk for adverse effects from Trimethoprim.

• Hyperkalemia: This is the most significant risk in the elderly, especially those on blood pressure medications. Fatal cases of high potassium have been linked to Trimethoprim use in seniors.
• Renal Clearance: Dose adjustments are almost always necessary as GFR naturally declines with age.
• Hematologic Sensitivity: Seniors are more likely to have marginal folate stores, making them more susceptible to drug-induced anemia or leukopenia.

In patients with a Creatinine Clearance (CrCl) between 15 and 30 mL/min, the dose must be reduced by 50%. Trimethoprim is moderately dialyzable; therefore, for patients on hemodialysis, a supplemental dose may be required after the procedure. It is generally avoided in patients with a CrCl less than 15 mL/min due to the high risk of toxicity.

There are no standardized guidelines for Trimethoprim dosing in hepatic impairment. However, in patients with Child-Pugh Class C (severe) cirrhosis, the drug should be used with extreme caution. Monitoring for signs of liver injury, such as increased bilirubin or transaminases, is recommended during therapy.

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure safety.

Trimethoprim is a competitive inhibitor of bacterial dihydrofolate reductase (DHFR). Its molecular structure mimics the pteridine portion of dihydrofolic acid. By binding to the active site of the DHFR enzyme, Trimethoprim prevents the conversion of dihydrofolic acid to its active form, tetrahydrofolic acid. This inhibition is highly selective; the drug's affinity for bacterial DHFR is 100,000 times higher than its affinity for human DHFR. This block in the folate synthesis pathway prevents the bacteria from producing thymidine and purines, which are essential for DNA synthesis. Consequently, the bacteria cannot replicate, a state known as bacteriostatic inhibition.

The antibacterial activity of Trimethoprim is concentration-independent, meaning its efficacy is primarily related to the time the concentration remains above the Minimum Inhibitory Concentration (MIC) for the target pathogen. Resistance to Trimethoprim can develop through several mechanisms, including the acquisition of plasmids that code for altered DHFR enzymes with reduced drug affinity, or through the overproduction of the normal DHFR enzyme.

| Parameter | Value |

|---|---|

| Bioavailability | 90% - 100% |

| Protein Binding | 42% - 46% |

| Half-life | 8 - 11 hours (Adults) |

| Tmax | 1 - 4 hours |

| Metabolism | Hepatic (10-20%) via CYP enzymes |

| Excretion | Renal 80% (mostly unchanged), Fecal <5% |

• Molecular Formula: C14H18N4O3
• Molecular Weight: 290.32 g/mol
• Solubility: Very slightly soluble in water; soluble in benzyl alcohol; sparingly soluble in chloroform and methanol.
• Description: Trimethoprim is a white to light yellow, odorless, bitter crystalline powder. It is a pyrimidine derivative, specifically a 2,4-diaminopyrimidine.

Trimethoprim is classified as a Dihydrofolate Reductase Inhibitor Antibacterial. It is unique in that it targets the second step of the folate synthesis pathway. It is often grouped with sulfonamides (which target the first step) because they are frequently used together to achieve a sequential blockade of bacterial folate synthesis, resulting in potent synergistic activity.